These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7832286)

  • 21. [Screening for Down's syndrome at week 10-14 by measuring fetal nuchal translucency thickness].
    Maymon R; Dreazen E; Weinraub Z; Bukovsky I; Herman A
    Harefuah; 1999 Nov; 137(9):353-7, 432. PubMed ID: 11419032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased nuchal translucency as a marker for fetal chromosomal defects.
    Taipale P; Hiilesmaa V; Salonen R; Ylöstalo P
    N Engl J Med; 1997 Dec; 337(23):1654-8. PubMed ID: 9385124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of routine screening for Down's syndrome on the significance of isolated fetal hydronephrosis.
    Thompson MO; Thilaganathan B
    Br J Obstet Gynaecol; 1998 Aug; 105(8):860-4. PubMed ID: 9746378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The comparison of microglia maturation in CNS of normal human fetuses and fetuses with Down's syndrome.
    Wierzba-Bobrowicz T; Lewandowska E; Schmidt-Sidor B; Gwiazda E
    Folia Neuropathol; 1999; 37(4):227-34. PubMed ID: 10705642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First trimester nuchal translucency: effective routine screening for Down's syndrome.
    Thilaganathan B; Sairam S; Michailidis G; Wathen NC
    Br J Radiol; 1999 Oct; 72(862):946-8. PubMed ID: 10673944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    BJOG; 2004 Jun; 111(6):521-31. PubMed ID: 15198778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Collagen type VI gene expression in the skin of trisomy 21 fetuses.
    von Kaisenberg CS; Brand-Saberi B; Christ B; Vallian S; Farzaneh F; Nicolaides KH
    Obstet Gynecol; 1998 Mar; 91(3):319-23. PubMed ID: 9491853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The anatomy of nuchal translucency at 10-14 weeks gestation in fetuses with trisomy 21: An incredible medical mystery.
    Nafziger E; Vilensky JA
    Clin Anat; 2014 Apr; 27(3):353-9. PubMed ID: 24488865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-trimester Down's syndrome screening by fetal nuchal translucency measurement in Taiwan.
    Jou HJ; Shih JC; Wu SC; Li TC; Tzeng CY; Hsieh FJ
    J Formos Med Assoc; 2001 Apr; 100(4):257-61. PubMed ID: 11393125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolated fetal echogenic intracardiac foci or golf balls: is karyotyping for Down's syndrome indicated?
    Thilaganathan B; Olawaiye A; Sairam S; Harrington K
    Br J Obstet Gynaecol; 1999 Dec; 106(12):1294-7. PubMed ID: 10609724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thymic extracellular matrix in Down's syndrome.
    Fonseca EC; Lannes-Vieira J; Villa-Verde DM; Savino W
    Braz J Med Biol Res; 1989; 22(8):971-4. PubMed ID: 2534476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humerus and femur length shortening in the detection of Down's syndrome.
    Nyberg DA; Resta RG; Luthy DA; Hickok DE; Williams MA
    Am J Obstet Gynecol; 1993 Feb; 168(2):534-8. PubMed ID: 8438923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyaluronan content of Wharton's jelly in healthy and Down syndrome fetuses.
    Raio L; Cromi A; Ghezzi F; Passi A; Karousou E; Viola M; Vigetti D; De Luca G; Bolis P
    Matrix Biol; 2005 Apr; 24(2):166-74. PubMed ID: 15890266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Log-linear allometry of fetal craniofacial growth in Down's syndrome.
    Cohen SR; Corrigan ML; Bookstein FL; Trotman CA; Burdi A; Barr M
    J Craniofac Surg; 1995 May; 6(3):184-9. PubMed ID: 9020687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation of a programme for the prenatal screening for Down's syndrome by ultrasonographic nuchal translucency measurement and serum determinations in the first trimester of pregnancy].
    Go AT; Hupkes HW; Lomecky M; Twisk J; Blankenstein JM; van Vugt JM
    Ned Tijdschr Geneeskd; 2005 Dec; 149(50):2795-9. PubMed ID: 16385832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.
    Aitken DA; Wallace EM; Crossley JA; Swanston IA; van Pareren Y; van Maarle M; Groome NP; Macri JN; Connor JM
    N Engl J Med; 1996 May; 334(19):1231-6. PubMed ID: 8606718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycosaminoglycans and proteoglycans in the skin of aneuploid fetuses with increased nuchal translucency.
    von Kaisenberg CS; Prols F; Nicolaides KH; Maass N; Meinhold-Heerlein I; Brand-Saberi B
    Hum Reprod; 2003 Dec; 18(12):2544-61. PubMed ID: 14645170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative evaluation of collagen type VI and SOD gene expression in the nuchal skin of human fetuses with trisomy 21.
    Quarello E; Guimiot F; Moalic JM; Simoneau M; Ville Y; Delezoide AL
    Prenat Diagn; 2007 Oct; 27(10):926-31. PubMed ID: 17602442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Down's syndrome screening with nuchal translucency at 12(+0)-14(+0) weeks and maternal serum markers at 14(+1)-17(+0) weeks: a prospective study.
    Rozenberg P; Malagrida L; Cuckle H; Durand-Zaleski I; Nisand I; Audibert F; Benattar C; Tribalat S; Cartron M; Lemarié P; Stoessel J; Capolagui P; Jansé-Marec J; Barbier D; Allouch C; Perdu M; Roberto A; Lahna Z; Giudicelli Y; Ville Y
    Hum Reprod; 2002 Apr; 17(4):1093-8. PubMed ID: 11925411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.